Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT02120469
Title Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase I
Variant Requirements No
Sponsors City of Hope Medical Center

triple-receptor negative breast cancer


Eribulin + Everolimus

Age Groups: adult
Covered Countries USA

No variant requirements are available.